TxCell recently announced new preclinical data in a presentation at the 18th Congress of the European Society for Organ Transplantation (ESOT), held in Barcelona last September. An oral presentation on alloantigen-specific regulatory T-cells (Treg) generated with a chimeric antigen receptor (CAR) reported on development of a CAR-Treg-based cellular immunotherapy for the prevention of graft rejection in the context of solid organ transplantation.
TxCell is a biotechnology company that develops platforms for innovative, personalized T-cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell is targeting a range of autoimmune diseases (both T-cell- and B-cell-mediated), including Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplant rejection.
www.txcell.com